ProShare Advisors
ELEV

ProShare Advisors’s Elevation Oncology ELEV Stock Holding History

ProShare Advisors’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,217
Closed -$3.17K – 2110
2025
Q1 		$3.17K Sell
12,217
-3,677
-23% -$2.1K ﹤0.01% 2079
2024
Q4 		$8.94K Buy
+15,894
New +$9.38K ﹤0.01% 2268

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

ProShare Advisors's ELEV Position: Q2 2025 in Review

ProShare Advisors sold out of Elevation Oncology (ELEV) in Q2 2025, closing a stake of 12,217 shares — an estimated $3.17K sold.

ProShare Advisors first reported a position in ELEV in Q4 2024 and held it in 2 quarters. The position peaked at $8.94K in Q4 2024. 65 funds tracked by Wall St. Rank hold ELEV as of Q2 2025.

  • ProShare Advisors reported no remaining Elevation Oncology position as of Q2 2025 after selling out during the quarter.
  • ProShare Advisors sold 12,217 Elevation Oncology shares in Q2 2025, an estimated $3.17K.
  • ProShare Advisors first reported a position in Elevation Oncology in Q4 2024 and held it in 2 quarters.
  • ProShare Advisors's Elevation Oncology position peaked at $8.94K in Q4 2024.
  • 65 funds tracked by Wall St. Rank held Elevation Oncology as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.